Literature DB >> 19278596

ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk?

Jean-Michel Halimi1, Albert Mimran.   

Abstract

Entities:  

Year:  2009        PMID： 19278596     DOI： 10.1007/s11906-009-0017-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  8 in total

1.  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael Farber; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carol Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann
Journal:  Arch Intern Med       Date:  2005-04-25

2.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Authors:  Janice Lea; Tom Greene; Lee Hebert; Michael Lipkowitz; Shaul Massry; John Middleton; Stephen G Rostand; Edgar Miller; Winifred Smith; George L Bakris
Journal:  Arch Intern Med       Date:  2005-04-25

3.  Relationship between vascular disease and age-associated changes in the human kidney.

Authors:  B L Kasiske
Journal:  Kidney Int       Date:  1987-05       Impact factor: 10.612

4.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

5.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

6.  Effect of losartan and enalapril on renal adaptation sodium restriction in rat.

Authors:  B Jover; D Saladini; N Nafrialdi; M Dupont; A Mimran
Journal:  Am J Physiol       Date:  1994-08

7.  Microalbuminuria and urinary albumin excretion: French clinical practice guidelines.

Authors:  J-M Halimi; S Hadjadj; V Aboyans; F-A Allaert; J-Y Artigou; M Beaufils; G Berrut; J-P Fauvel; H Gin; A Nitenberg; J-C Renversez; E Rusch; P Valensi; D Cordonnier
Journal:  Diabetes Metab       Date:  2007-08-16       Impact factor: 6.041

Review 8.  A note on competing risks in survival data analysis.

Authors:  J M Satagopan; L Ben-Porat; M Berwick; M Robson; D Kutler; A D Auerbach
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640
  8 in total
  2 in total

Review 1.  Optimal therapy in hypertensive subjects with diabetes mellitus.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

2.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.